Mandate

Vinge advises Blugiallo in connection with its financing round

January 12, 2023 M&A

Vinge has advised Blugiallo and its founders in connection with a financing round with the purpose of expanding the business within existing and new markets.

Blugiallo is a Swedish menswear company, founded in 2015 by Alexander Moström and Daniel Apler. By questioning systematic problems within the fashion industry, such as overproduction and return rates, Blugiallo focuses entirely on producing “on demand”, where all products are customized to each individual customer. Blugiallo’s long-term vision is to change the way people buy clothing by offering the “superior feeling gained from a uniquely produced wardrobe” through its e-commerce and physical showrooms.

The financing round included existing and new investors.

Vinge’s team consisted of Karl Klackenberg and Viktor Lennartsson.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025